Russia has developed an mRNA-based cancer vaccine, which will be distributed free of cost to cancer patients, according to a report by Russian news agency TASS. Andrey Kaprin, General Director of the Radiology Medical Research Center under the Russian Ministry of Health, shared the development on Radio Rossiya.
The vaccine, created in collaboration with multiple research institutions, is expected to be available for public use by early 2025. Pre-clinical trials demonstrated the vaccine’s ability to suppress tumor growth and prevent potential metastases, stated Alexander Gintsburg, Director of the Gamaleya National Research Center for Epidemiology and Microbiology.
Messenger RNA (mRNA) vaccines work by instructing cells to produce proteins or protein fragments resembling parts of the targeted virus or disease-causing agent. These proteins then trigger an immune response, enabling the body to combat the disease effectively.
In a previous interview with TASS, Gintsburg mentioned that artificial intelligence (AI) could revolutionize the creation of personalized cancer vaccines. Neural networks could reduce the computational time for designing tailored mRNA vaccines from several hours to just 30–60 minutes.
